Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients.
Our lead product candidate is tucatinib, an investigational, orally bioavailable, potent HER2-selective small molecule tyrosine kinase inhibitor (TKI). We are conducting a randomized, double-blind, placebo-controlled pivotal trial called HER2CLIMB, which is comparing tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with locally advanced or metastatic HER2+ breast cancer with and without brain metastases. Additional details on HER2CLIMB can be found at www.HER2CLIMB.com or www.clinicaltrials.gov.
We are also developing a Chk1 kinase inhibitor and an antibody against an immuno-oncology target known as TIGIT, both of which are currently in preclinical development.
We are headquartered in Seattle, Washington, and our common stock trades on The NASDAQ Global Market under the symbol "CASC".